study design

Follow-up Schedule

Parameters Detailed information Screening Baseline 1 Y 2 Y 3 Y 4 Y 5 Y Improvement or
deterioration of
clinical outcomes
Hard outcomes
(ESRD, CV
outcomes)
Informed consent O
Demo graphic O
information O
Medical history
Medications Hypertensive medications O O O O O O O O
Immunosuppressant O O O O O O O O
Questionn aires Health questionnaires (including smoking) O O O O O O O O
KDQOL-SF version 1.3 questionnaires O O O O O O O O
Semi-food frequency questionnaires O O O O O O O O
PedsQL 4.0 Generic Core Scales (Children) O O
Blood laboratory findings CBC (white blood cell count, platelet, haemoglobin) O O O O O O O O
Chemistry (calcium, phosphorus, glucose, blood urea nitrogen, uric acid, total protein, albumin, total bilirubin, alkaline phosphatase, AST, ALT) O O O O O O O O
IDMS-traceable Cr, eGFR O O O O O O O O
Lipid panel (total cholesterol, triglyceride, high-density lipoprotein, low density lipoprotein) O O O O O O O O
Electrolyte panel (sodium, potassium, chloride) O O O O O O O O
Total CO2 O O O O O O O O
C-reactive protein O O O O O O O O
Serology (HBsAg, HBsAb, Anti-HCV, HIV, VDRL) O
Anti-dsDNA, FANA, FANA titre, ANCA, PR3, MPO O
Complement 3, 4 O
ASO, rheumatoid factor, Cryoglobulin O
Urine laboratory findings Random urine protein O O O O O O O O
Random urine microalbumin O O O O O O O O
Random urine creatinine O O O O O O O O
Urinalysis protein O O O O O O O O
Urinalysis RBC O O O O O O O O
Kidney biopsy Biopsy results and images including LM, IF and EM O
Report of diagnosis O
Total number of glomeruli O
Total number of global sclerosis/segmental sclerosis/crescent O